The Sugar Beat

 
 

  • VERTIS-CV Results 'Disappoint,' Raise More Questions The VERTIS-CV trial results presented at the ADA meeting raise more questions about the benefits of SGLT2 inhibitors than they answer, says Dr Harpreet Bajaj.
  • Is COVID-19 Fueling the Fire of Opinion-Based Medicine? This pandemic is causing people to turn to the 'pseudosciences' in their desperation to quickly save the world, writes Harpreet Bajaj.
  • The Links Between COVID-19 and Diabetes, Known and Unknown Dr Harpreet Bajaj summarizes the known and unknown links between diabetes and COVID-19, focusing on three clinical questions.
  • Cardios, Nephros, PCPs -- We're All Diabetologists Now Newer diabetes medications are proving effective in reducing CV events, hospitalizations for heart failure, and progression to dialysis. So where do these drugs belong?
  • Top 5 Diabetes Highlights From 2019 For the first time in several years, a cardiovascular outcomes trial may not be the most exciting diabetes news of the year. Here are 2019's highlights from Dr Harpreet Bajaj.
  • Recreational Marijuana in Diabetes: Not All Fun and Games   Dr Harpreet Bajaj discusses the potential harms of recreational cannabis use in people with type 1 and type 2 diabetes.
  • 'Poised on a Paradigm Shift': The REWIND and DECLARE Trials   Drs Harpreet Bajaj and Akshay Jain, coauthors of the Sugar Beat column, come together to discuss the results and clinical implications of the REWIND and DECLARE trials.
  • CREDENCE Takes SGLT2 Inhibitors 'to the Next Level' What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.
  • Fielding the Dangers of Fasting and Feasting With Diabetes Are you prepared to safely guide your Muslim patients with diabetes through Ramadan, their holy month of fasting? Here's what you need to know.
  • Diabetes 360: A Plan to Quell the 'Tsunami' of Diabetes Diabetes Canada's 360° framework can revolutionize diabetes prevention policies across the globe, says Harpreet Bajaj.
  • Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' Dr Akshay Jain discusses the potential implications of a generic DPP-4 inhibitor for the management of type 2 diabetes that may soon enter the US market.
  • The Artificial Pancreas Has Arrived in Canada: What to Expect Dr Harpreet Bajaj discusses the first artificial pancreas that has been approved for use in Canada--what to expect, anticipated challenges, and learnings from experiences in the United States.
  • Surviving the Holidays With Diabetes Celebrating the holidays doesn't have to be a choice between losing glycemic control or missing out on the fun. Dr Akshay Jain provides some tips to help guide discussions on safe holiday eating.
  • Dispelling the Myths About Obesity Is obesity a choice? Are people just lazy or suffering from 'food addiction'? Dr Akshay Jain responds to the results of a recent Medscape poll and says it's time to dispel the myths about obesity.
  • SGLT2 Inhibitors: Unreal Primary Prevention? These diabetes drugs offer cardiovascular benefits, but only in diabetes patients who already have CV disease, the author argues.
  • Alcohol Advice Demands Full Disclosure First What do you tell patients who ask about 'safe' alcohol intake--or who inquire about your own drinking habits?
  • CANVAS: Straight Talk Needed on Amputation Risk Can a meta-analysis of two different studies or data from observational studies overcome the clinical concern about the clear-cut amputation risk with canagliflozin seen in the CANVAS trial?